Table 3.

TREK-1 in CNS pathologies.

Pathology	TREK-1 expression			Potential treatment	References
	Immunofluorescence	mRNA	Protein
Depression	nd	nd	↑ in the frontal cortex 3 weeks after CMS in rat No change in the hippocampus	TREK-1 blockers as potential treatment in depression	Chen et al., 2015
			Fluoxetine per os daily for 3 weeks
			Reverse TREK-1 overexpression in the frontal cortex
Ischemia	Broad distribution in the cortex and CA1 (glia and neurons)	↑ in the hippocampus at 3 and 30 days after BCAL In situ hybridization: ↑ in the cortex and hippocampus 7 and 30 days after BCAL (Xu et al., 2004)	in the hippocampus 7 and 30 days after MCAO	TREK-1 openers as potential treatment in ischemia	Wang et al., 2012
	↑ in the cortex and the hippocampus after 3, 7, and 30 days after MCAO
Pain perception	TREK-1 expression in DRG sensory neurons	↑ in DRG of CCI mice	↑ in DRG of CCI mice	TREK-1 openers as potential analgesics	Alloui et al., 2006; Han et al., 2016
Post-stroke depression	Broad distribution in PFC, CA1, CA3, and DG	No treatment, after 31 days of MMCAO			Lin et al., 2015
		↑ in PFC, CA3 and DG	↑ in PFC, CA1, CA3 and DG	TREK-1 blockers as potential treatment in PSD
		Escitalopram (3 weeks)
		↓ in PFC, CA3 and DG	↓ in PFC, CA1,CA3 and DG